Mary O’Brien

26.9k citations
274 papers · 17.5k · 4 hit papers · h-index 53

Impact in

  • Oncology top 0.05%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Lung Cancer Treatments and Mutations 95
    • Lung Cancer Diagnosis and Treatment 45
    • Occupational and environmental lung diseases 27
    • Lung Cancer Research Studies 50
    • Cancer Immunotherapy and Biomarkers 28
    • Cancer Treatment and Pharmacology 18
    • Colorectal Cancer Treatments and Studies 14

Mary O’Brien

267 papers receiving 17.1k citations

Mary O’Brien's Hit Papers

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% 2021 · 654 citations
6540+9+19Years since publication2.0k4.0k6.0k

Peers

Mary O’Brien
Comparison fields: 5 of 179
  • Oncology 9.5k
  • Pulmonary and Respiratory Medicine 6.2k
  • Cancer Research 1.6k
  • Immunology 1.5k
  • Pathology and Forensic Medicine 602
Replace Deepa Naishadham with:
Deepa Naishadham United States
Fabrice Barlési France
Ramaswamy Govindan United States
William E. Gooding United States
David P. Ryan United States
Phyllis A. Wingo United States
Gary K. Schwartz United States
Corey J. Langer United States
Dae Seog Heo South Korea
Neal J. Meropol United States
Mary O’Brien relative to Deepa Naishadham United States Deepa Naishadham's profile →
Citations per field
00.5×10×14×
Deepa Naishadham · 1×
Citations per year

Countries citing papers authored by Mary O’Brien

Since Specialization
Citations

This map shows the geographic impact of Mary O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary O’Brien more than expected).

Fields of papers citing papers by Mary O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary O’Brien. The network helps show where Mary O’Brien may publish in the future.

Co-authors

The 25 scholars most cited alongside Mary O’Brien, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary O’Brien Line = papers co-authored together Mary O’Brien links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 274 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Hit paper breakdown →
20167183
2
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Hit paper breakdown →
1997691
3
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Hit paper breakdown →
2021654
4 2006452
5 2017366
6 2004356
7
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Hit paper breakdown →
2015289
8 1995267
9 2017257
10 2001239
11 2014237
12 2008175
13 2015139
14 1983132
15 2000127
16 2008125
17 2014123
18 2006119
19 1994116
20 2001116

About Mary O’Brien

Mary O’Brien is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Epidemiology and Molecular Biology, having authored 274 papers that have together received 17.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (95 papers), Lung Cancer Research Studies (50 papers), Lung Cancer Diagnosis and Treatment (45 papers), Cancer Immunotherapy and Biomarkers (28 papers), Occupational and environmental lung diseases (27 papers), Cancer Genomics and Diagnostics (18 papers), Cancer Treatment and Pharmacology (18 papers) and Colorectal Cancer Treatments and Studies (14 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (6.2k citations), Cancer Research (1.6k citations), Immunology (1.5k citations) and Pathology and Forensic Medicine (602 citations). Mary O’Brien has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Julie R. Brahmer, Martin Reck, Maya Gottfried, Ali Tafreshi, Suman Rao, Rina Hui, Nir Peled, Delvys Rodríguez‐Abreu, Tibor Csőszi and Sinéad Cuffe. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Journal of Thoracic Oncology, Lung Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact